Amgen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Amgen and other ETFs, options, and stocks.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

26,700

Employees26,700

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

26,700

Employees26,700

AMGN Key Statistics

Market cap

145.78B

Market cap145.78B

Price-Earnings ratio

21.78

Price-Earnings ratio21.78

Dividend yield

3.18%

Dividend yield3.18%

Average volume

2.16M

Average volume2.16M

High today

—

High today—

Low today

—

Low today—

Open price

$270.00

Open price$270.00

Volume

0.00

Volume0.00

52 Week high

$329.72

52 Week high$329.72

52 Week low

$211.71

52 Week low$211.71

AMGN News

Benzinga 4d

How Is The Market Feeling About Amgen? - Amgen - Benzinga

Loading... Loading... Amgen's AMGN short percent of float has fallen 5.77% since its last report. The company recently reported that it has 10.47 million share...

Simply Wall St 4d

Amgen's investors will be pleased with their respectable 70% return over the last five years - Simply Wall St

Amgen Inc. ( ) shareholders might be concerned after seeing the share price drop 15% in the last quarter. On the bright side the share price is up over the last...

Yahoo Finance 6d

Amgen Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

In the latest market close, Amgen (AMGN) reached $264.07, with a -0.59% movement compared to the previous day. This change lagged the S&P 500's daily loss of 0....

Analyst ratings

48%

of 31 ratings

Buy

48.4%

Hold

38.7%

Sell

12.9%

More AMGN News

Benzinga 6d

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Loading... Loading... Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic...

TipRanks 7d

Amgen to present Tezspire Phase 2a COPD data at ATS 2024

Amgen “provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE(R) in chronic obstructive pulmonary disease, or COPD, which were accep...